Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056870 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of Spherical Soft Contact Lenses, Toric Soft Contact Lenses and Spectacles in Low Astigmats
A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 174
- Enrollment target
- 13
- Study locations
NCT05056870: Completed NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT05056870 is a NA study of Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 174 participants, above the 131-participant average among 20 other Visual Acuity trials with a reported enrollment target (33% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056870, a NA study of Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 174 participants
- Enrollment target
- 13
- Study locations
Study Summary
This will be a 5-visit, randomized, partially single-masked, bilateral wear, dispensing, 2-treatment × 2-period crossover study with spectacle-wear washout and wash-in periods.
Primary Outcome
Visual Acuity was collected for each subject eye at distance (4 meter) using a Logarithm of Minimal Angle of Resolution (logMAR) visual acuity scale. This was evaluated under high luminance and high contrast conditions (HLHC) at 4 meters from Early Treatment Diabetic Retinopathy Study (ETDRS) charts at the 1-week follow-up visit. A value of 0.0 logMAR is equivalent to 20/20 Snellen Visual Acuity. Lower values of visual acuity indicate better vision. The average logMAR Visual Acuity was reported
Conditions Studied
Interventions
- DEVICE ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism
- DEVICE ACUVUE Oasys 1-Day with HydraLuxe Technology
Study Locations (13)
Ohio
- University Hospitals of Cleveland Medical Center - Cleveland
- ProCare Vision Center - Granville
- Professional Visioncare Inc. - Westerville
Florida
- Sabal Eye Care - Longwood
- Maitland Vision Center - Maitland
California
- Eyecenter Optometric - Rocklin
Hawaii
- Windward Vision Ctr Associates Inc. - Kaneohe
Indiana
- Indiana University School of Optometry - Bloomington
Missouri
- Advanced Eye Care - Raytown
New York
- Sacco Eye Group - Vestal
Tennessee
- Total Eye Care - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2022-03-03 |
| Phase | NA |
What the finished NCT05056870 record still lists
NCT05056870 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 131-participant average among 20 other Visual Acuity trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions - of which ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism is the first listed.
NCT05056870 lists 13 locations in 10 states (Ohio, Florida, California).
Frequently Asked Questions
What is clinical trial NCT05056870 about?
NCT05056870 is a clinical study titled "Clinical Evaluation of Spherical Soft Contact Lenses, Toric Soft Contact Lenses and Spectacles in Low Astigmats". This will be a 5-visit, randomized, partially single-masked, bilateral wear, dispensing, 2-treatment × 2-period crossover study with spectacle-wear washout and wash-in periods.
What is the current status of trial NCT05056870?
This trial is currently completed. It is a NA study. The enrollment target is 174 participants. The study started on 2021-09-15. Estimated completion is 2022-03-03.
What conditions does trial NCT05056870 study?
This clinical trial studies the following conditions: Visual Acuity.
What interventions are being tested in trial NCT05056870?
The interventions under investigation include: ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism (DEVICE), ACUVUE Oasys 1-Day with HydraLuxe Technology (DEVICE).
Who is sponsoring clinical trial NCT05056870?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056870 being conducted?
This trial has 13 study locations across California, Florida, Hawaii, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Acuity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05056870's enrollment target sits among peer trials
174 5th of 20 higher than 16 of 20 other Visual Acuity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Effect of Scatter on Visual Performance
RECRUITING · NA
-
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
COMPLETED · NA
-
Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
COMPLETED · NA
-
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
COMPLETED · NA
-
Clinical Evaluation of Approved Contact Lenses
COMPLETED · NA
-
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI